Findings of Research Misconduct, 25273-25275 [2024-07575]
Download as PDF
<![CDATA[
25273
Federal Register / Vol. 89, No. 70 / Wednesday, April 10, 2024 / Notices
information from applicants who wish
to be considered for those options. The
NHSC Comprehensive Behavioral
Health Services Checklist collects
information to ascertain whether
behavioral health providers are
practicing in a community-based setting
that provides access to comprehensive
behavioral health services. The NHSC
Site Application collects information
used for determining the eligibility of
sites for the assignment of NHSC health
professionals and to verify the need for
NHSC clinicians.
A 60-day notice published in the
Federal Register on January 23, 2024,
vol. 88, No. 249; pp. 90191–92. There
were no public comments.
Need and Proposed Use of the
Information: The need and proposed
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
use of this information collection is to
assess an LRP applicant’s eligibility and
qualifications for the LRP, and to
determine LRP applicants’ Spanish
language proficiency if relevant to their
application, and to obtain information
for NHSC site applicants. The NHSC
LRP application asks for personal,
professional, and financial/loan
information.
Likely Respondents: Likely
respondents include licensed primary
care medical, dental, and behavioral
health providers who are employed or
seeking employment and are interested
in serving underserved populations.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total
responses
Average burden
per response
(in hours)
Total burden
hours
NHSC LRP Application .......................................................................................
Authorization for Disclosure of Loan Information Form ......................................
Privacy Act Release Authorization Form ............................................................
Verification of Disadvantaged Background Form ...............................................
Private Practice Option Form ..............................................................................
NHSC Comprehensive Behavioral Health Services Checklist ...........................
NHSC Spanish Language Assessment Proficiency Test Form .........................
NHSC Site Application (including recertification) ................................................
9,020
7,150
303
660
330
4,400
3,006
4,070
1
1
1
1
1
1
1
1
9,020
7,150
303
660
330
4,400
3,006
4,070
1.00
0.10
0.10
0.50
0.10
0.13
0.50
0.50
9,020
715
30
330
33
572
1,503
2,035
Total .............................................................................................................
28,939
........................
28,939
..........................
14,238
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–07590 Filed 4–9–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against
Gian-Stefano Brigidi, Ph.D.
(Respondent), who was a Postdoctoral
Fellow, Department of Neurobiology,
University of California San Diego
(UCSD), and was an Assistant Professor,
Department of Neurobiology, University
of Utah (UU). Respondent engaged in
research misconduct in research
supported by U.S. Public Health Service
(PHS) funds, specifically National
Institute of Mental Health (NIMH),
National Institutes of Health (NIH),
grant F32 MH110141, National Human
Genome Research Institute (NHGRI),
NIH, grant T32 HG000044, National
Institute of Neurological Disorders and
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
responses per
respondent
VerDate Sep<11>2014
18:10 Apr 09, 2024
Jkt 262001
Stroke (NINDS), NIH, grant P30
NS047101, and National Library of
Medicine (NLM), NIH, grant T15
LM011271. The research was included
in grant applications submitted for PHS
funds, specifically R01 NS131809–01,
R01 NS133405–01, DP2 NS127276–01,
and R01 NS111162–01A1 submitted to
NINDS, NIH, and R21 MH121860–01,
R21 MH121860–01A1, F32 MH110141–
01, F32 MH110141–01A1, and F32
MH110141–01AS1 submitted to NIMH,
NIH. The administrative actions,
including supervision for a period of
five (5) years, were implemented
beginning on March 24, 2024, and are
detailed below.
FOR FURTHER INFORMATION CONTACT:
Sheila Garrity, JD, MPH, MBA, Director,
Office of Research Integrity, 1101
Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Gian-Stefano Brigidi, Ph.D.,
University of California San Diego
(UCSD) and University of Utah (UU):
Based on the report of an assessment
conducted by UU, and inquiry
conducted by UCSD, the Respondent’s
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
admission, and additional analysis
conducted by ORI in its oversight
review, ORI found that Dr. Gian-Stefano
Brigidi, former Postdoctoral Fellow in
the Department of Neurobiology, UCSD,
and former Assistant Professor,
Department of Neurobiology, UU,
engaged in research misconduct in
research supported by PHS funds,
specifically NIMH, NIH, grant F32
MH110141, NHGRI, NIH, grant T32
HG000044, NINDS, NIH, grant P30
NS047101, and NLM, NIH, grant T15
LM011271. The research was included
in grant applications submitted for PHS
funds, specifically R01 NS131809–01,
R01 NS133405–01, DP2 NS127276–01,
and R01 NS111162–01A1 submitted to
NINDS, NIH, and R21 MH121860–01,
R21 MH121860–01A1, F32 MH110141–
01, F32 MH110141–01A1, and F32
MH110141–01AS1 submitted to NIMH,
NIH.
ORI found that Respondent engaged
in research misconduct by knowingly or
intentionally falsifying and/or
fabricating data and results by
manipulating primary data values to
falsely increase the n-value,
manipulating fluorescence micrographs
and their quantification graphs to
augment the role of ITFs in murine
hippocampal neurons, and/or
E:\FR\FM\10APN1.SGM
10APN1
ddrumheller on DSK120RN23PROD with NOTICES1
25274
Federal Register / Vol. 89, No. 70 / Wednesday, April 10, 2024 / Notices
manipulating confocal images that were
obtained through different experimental
conditions in twenty (20) figures of one
(1) published paper and four (4) PHS
grant applications, one (1) panel of one
(1) poster, and seven (7) slides of one (1)
presentation:
• Genomic Decoding of Neuronal
Depolarization by Stimulus-Specific
NPAS4 Heterodimers. Cell. 2019 Oct
3;179(2):373–391.e27. doi: 10.1016/
j.cell.2019.09.004 (hereafter referred to
as ‘‘Cell 2019’’).
• Genomic mechanisms linking
neuronal activity history with present
and future functions. Poster for ‘‘The
Brigidi Lab—a neuronal activity lab in
the Department of Neurobiology at the
University of Utah’’ (hereafter referred
to as the ‘‘UU Department of
Neurobiology poster’’).
• Decoding neural circuit stimuli into
spatially organized gene regulation.
Presentation presented to the UU
Department of Neurobiology & Anatomy
on January 23, 2020 (hereafter referred
to as ‘‘UU Department of Neurobiology
presentation’’).
• DP2 NS127276–01, ‘‘Decoding
neuronal activity history at the genome
through the spatially segregated
inducible transcription factors,’’
submitted to NINDS, NIH, on August 20,
2020, Awarded Project Dates: September
15, 2021–August 1, 2023.
• F32 MH110141–01, ‘‘Regulation of
excitatory-inhibitory balance by the
local translation of the immediate early
gene Npas4,’’ submitted to NIMH, NIH,
on August 10, 2015.
• F32 MH110141–01A1, ‘‘Regulation
of Excitatory-Inhibitory Balance by
Local Translation of the Immediate
Early Gene Npas4,’’ submitted to NIMH,
NIH, on December 8, 2015, Awarded
Project Dates: August 1, 2016–July 31,
2018.
• F32 MH110141–01A1S1,
‘‘Regulation of Excitatory-Inhibitory
Balance by Local Translation of the
Immediate Early Gene Npas4,’’
submitted to NIMH, NIH, on December
8, 2016, Awarded Project Dates:
December 1, 2016–July 31, 2017.
The falsified and/or fabricated data
also were included in twenty-three (23)
figures in the following five (5) PHS
grant applications:
• R01 NS131809–01, ‘‘Regulation and
function of dendritic mRNA that
encodes the neuronal transcription
factor Npas4,’’ submitted to NINDS,
NIH, on June 6, 2022.
• R01 NS133405–01, ‘‘Assessing the
impact of the inducible transcription
factor NPAS4 on spatial tuning in the
mouse hippocampus,’’ submitted to
NINDS, NIH, on October 5, 2022.
VerDate Sep<11>2014
18:10 Apr 09, 2024
Jkt 262001
• R01 NS111162–01A1, ‘‘Molecular
and cellular mechanisms underlying
activity dependent gene regulation in
neurons,’’ submitted to NINDS, NIH, on
March 5, 2019, Awarded Project Dates:
December 15, 2019–November 30, 2024.
• R21 MH121860–01, ‘‘Identification
of dendritically-localized transcription
factor mRNAs as a mechanism for
conveying multiple streams of
information to the nucleus,’’ submitted
to NIMH, NIH, on February 19, 2019.
• R21 MH121860–01A1,
‘‘Identification of dendritically-localized
transcription factor mRNAs,’’ submitted
to NIMH, NIH, on March 16, 2020.
Specifically, ORI found that:
1. Respondent knowingly or
intentionally combined two to three real
data sets and two to five fabricated data
sets to falsely increase the n-values
reported in:
• Figures 1B, 1D, 1E, 1G, 1I, 1J, 1M–
1O, 1Q–1T, S2B–S2D, S2F–S2H, S3I,
S3L, S3M, and S6H of Cell 2019 and
Slides 6–10, 13, and 28 of the UU
Department of Neurobiology
presentation representing the
quantification of NPAS4
immunohistofluorescence.
• Figures 2H, 2I, 2K, 2P, 3C, 3E, 4D–
4G, 4K–4N, 4P–4Q, S3G, S5B, and S5C
of Cell 2019 representing the
quantification of Npas4 mRNA or puroPLA puncta.
• Figures S1E, S1G, and S1H of Cell
2019 representing the quantification of
whole-cell clamp recordings of CA1 PN.
• Figures 2 (lower panel) and 3c of
F32 MH110141–01, Figures 1g, 2b, 2d,
and 4 of F32 MH110141–01A1S1, and
Figures 1g, 2b, 2d, and 4 of F32
MH110141–01A1 representing time
points of NPAS4 quantification after no
stimulation or post-stimulation in the
alveus or radiatum SR, SO, SP, SLM,
with or without the addition of an
inhibitor.
2. Respondent knowingly or
intentionally manipulated confocal
images that were obtained through
different experimental conditions in:
• Figures 1A, 1C, and 1F of Cell 2019
and Slides 6–9 of the UU Department of
Neurobiology presentation representing
confocal images of hippocampal slices
immunostained for NPAS4 and Neu.
• Figures S2A and S2E of Cell 2019
by manipulating and misrepresenting
the GFP signals as NPAS4 signals in
wildtype mice.
• Figures 1H, 1L, 1P, S3K, S6F, and
S6G of Cell 2019 and Slides 9 and 28
of the UU Department of Neurobiology
presentation by manipulating the raw
images of hippocampal slices
immunostained with NPAS4 and Neu
and/or ARNT1 or ARNT2 by generating
a mask of NPAS4 immunofluorescent
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
signal through GFP signal from tissue
obtained from Thy1–GFP mice to
intentionally enhance the appearance of
the dendritic NPAS4 signal.
• Figures S6F and S6G of Cell 2019
by manipulating the raw images of
hippocampus slices by overlaying a GFP
channel over ARNT1 channel and using
the multiply feature in Photoshop to
restrict ARNT1 signal through GFP to
enhance the ARNT1 signal in three
panels.
• Slides 7, 9, and 28 of the UU
Department of Neurobiology
presentation by manipulating six images
representing post-stimulation with
different time points by using a GFP
mask overlaid on top of raw NPAS4
immunofluorescence.
• Figure 4 of DP2 NS127276–01 and
panel 1 of the UU Department of
Neurobiology poster representing twelve
images in columns 2–4 labeled EGR,
FOS, ATF4 by mislabeling the
microscope images as
immunofluorescent stained with
antibodies against EGR, FOS, and ATF4
when they actually were stained with
anti-NPAS4 and selected images to
support the immunofluorescence data in
the ITF induction graphs.
• Figure 5 of DP2 NS127276–01
representing two confocal images in the
far-right column by intentionally and
selectively enhancing the brightness of
the anti-NPAS4 immunofluorescent
channel within the dashed box and left
brightness unchanged in surrounding
areas of the images.
• Figure 6 of DP2 NS127276–01 in
twelve images in columns 2–5 labeled
Egr2, Fos, and Atf4 by intentionally
mislabeling the microscope images as
RNA in situ hybridization with probes
against Egr2, Fos, and Atf4 when they
actually were stained with NPAS4
probes and intentionally selecting and
quantifying images in the quantification
graphs to support the conclusions of the
grant application.
3. Respondent knowingly or
intentionally manipulated the
fluorescence micrographs and their
quantification graphs to augment the
role of ITFs in murine hippocampal
neurons in Figures 2B–2G, 2J, 2L–2O,
3B, 3D, 3F–3H, 4C, 4J, 4O, S1A–S1D,
S1F, S1I–S1J, S3A–S3F, S3H, S3J, S3N–
S3T, S5D–S5G, and S6A–S6E of Cell
2019; the falsified/fabricated data also
were included in Figures 2B–2H, 3, 4B–
4E, and 5C–5G of R21 MH121860–01,
Figures 2, 3B–3E, 4B–4C, 4E–4I, and
5B–5E of R21 MH121860–01A1, Figures
3, 5, 6B, 7, 8, 10B–10D, 11A–11C, and
11E–11F in R01 NS131809–01, Figure 8
of R01 NS133405–01, and Figures 3B–
3C, 3E–3I, 4B–4I, 5, 9, 10B–10E, and 11–
12 of R01 NS111162–01A1.
E:\FR\FM\10APN1.SGM
10APN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 70 / Wednesday, April 10, 2024 / Notices
Respondent entered into a Voluntary
Settlement Agreement (Agreement) and
voluntarily agreed to the following:
(1) Respondent will have his research
supervised for a period of five (5) years
beginning on March 24, 2024 (the
‘‘Supervision Period’’). Prior to the
submission of an application for PHS
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of five (5) years
from the effective date of the
Agreement. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the data
presented in the proposed application,
report, manuscript, or abstract are
supported by the research record.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing him submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
VerDate Sep<11>2014
18:10 Apr 09, 2024
Jkt 262001
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that his
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that he has not
participated in any capacity in PHSsupported research.
(5) During the Supervision Period,
Respondent will exclude himself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
(6) Respondent will request that the
following paper be corrected or
retracted:
• Cell. 2019 Oct 3;179(2):373–
391.e27. doi: 10.1016/j.cell.2019.09.004.
Respondent will copy ORI and the
Research Integrity Officer at UCSD on
the correspondence with the journal.
Dated: April 4, 2024.
Sheila Garrity,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
[FR Doc. 2024–07575 Filed 4–9–24; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery (NIH)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects,
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Mikia P. Currie, Chief
Project Clearance Officer, Office of
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
25275
Policy for Extramural Research
Administration, 6705 Rockledge Drive,
Suite 350, Bethesda, Maryland, 20892 or
call non-toll-free number (301) 435–
0941 or email your request, including
your address to: curriem@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Proposed Collection Title: Generic
Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery, 0925–EXTENSION, exp., date
6/30/2024, National Institutes of Health
(NIH).
Need and Use of Information
Collection: We are not requesting
changes for this submission. The
proposed information collection
provides a means to garner qualitative
customer and stakeholder feedback in
an efficient, timely manner, in
accordance with the Administration’s
commitment to improving service
delivery. By qualitative feedback we
mean information that provides useful
insights on perceptions and opinions.
This information, however, is not
statistical surveys that yield quantitative
results, which can be generalized to the
population of study. This feedback will
provide information about NIH’s
customer or stakeholder perceptions,
experiences, and expectations, provide
an early warning of issues with service,
or focus attention on areas where
communication, training, or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative,
and actionable communications
between NIH and its customers and
stakeholders. It will also allow feedback
E:\FR\FM\10APN1.SGM
10APN1
]]>Agencies
[Federal Register Volume 89, Number 70 (Wednesday, April 10, 2024)]
[Notices]
[Pages 25273-25275]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07575]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Gian-
Stefano Brigidi, Ph.D. (Respondent), who was a Postdoctoral Fellow,
Department of Neurobiology, University of California San Diego (UCSD),
and was an Assistant Professor, Department of Neurobiology, University
of Utah (UU). Respondent engaged in research misconduct in research
supported by U.S. Public Health Service (PHS) funds, specifically
National Institute of Mental Health (NIMH), National Institutes of
Health (NIH), grant F32 MH110141, National Human Genome Research
Institute (NHGRI), NIH, grant T32 HG000044, National Institute of
Neurological Disorders and Stroke (NINDS), NIH, grant P30 NS047101, and
National Library of Medicine (NLM), NIH, grant T15 LM011271. The
research was included in grant applications submitted for PHS funds,
specifically R01 NS131809-01, R01 NS133405-01, DP2 NS127276-01, and R01
NS111162-01A1 submitted to NINDS, NIH, and R21 MH121860-01, R21
MH121860-01A1, F32 MH110141-01, F32 MH110141-01A1, and F32 MH110141-
01AS1 submitted to NIMH, NIH. The administrative actions, including
supervision for a period of five (5) years, were implemented beginning
on March 24, 2024, and are detailed below.
FOR FURTHER INFORMATION CONTACT:
Sheila Garrity, JD, MPH, MBA, Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Gian-Stefano Brigidi, Ph.D., University of California San Diego
(UCSD) and University of Utah (UU): Based on the report of an
assessment conducted by UU, and inquiry conducted by UCSD, the
Respondent's admission, and additional analysis conducted by ORI in its
oversight review, ORI found that Dr. Gian-Stefano Brigidi, former
Postdoctoral Fellow in the Department of Neurobiology, UCSD, and former
Assistant Professor, Department of Neurobiology, UU, engaged in
research misconduct in research supported by PHS funds, specifically
NIMH, NIH, grant F32 MH110141, NHGRI, NIH, grant T32 HG000044, NINDS,
NIH, grant P30 NS047101, and NLM, NIH, grant T15 LM011271. The research
was included in grant applications submitted for PHS funds,
specifically R01 NS131809-01, R01 NS133405-01, DP2 NS127276-01, and R01
NS111162-01A1 submitted to NINDS, NIH, and R21 MH121860-01, R21
MH121860-01A1, F32 MH110141-01, F32 MH110141-01A1, and F32 MH110141-
01AS1 submitted to NIMH, NIH.
ORI found that Respondent engaged in research misconduct by
knowingly or intentionally falsifying and/or fabricating data and
results by manipulating primary data values to falsely increase the n-
value, manipulating fluorescence micrographs and their quantification
graphs to augment the role of ITFs in murine hippocampal neurons, and/
or
[[Page 25274]]
manipulating confocal images that were obtained through different
experimental conditions in twenty (20) figures of one (1) published
paper and four (4) PHS grant applications, one (1) panel of one (1)
poster, and seven (7) slides of one (1) presentation:
Genomic Decoding of Neuronal Depolarization by Stimulus-
Specific NPAS4 Heterodimers. Cell. 2019 Oct 3;179(2):373-391.e27. doi:
10.1016/j.cell.2019.09.004 (hereafter referred to as ``Cell 2019'').
Genomic mechanisms linking neuronal activity history with
present and future functions. Poster for ``The Brigidi Lab--a neuronal
activity lab in the Department of Neurobiology at the University of
Utah'' (hereafter referred to as the ``UU Department of Neurobiology
poster'').
Decoding neural circuit stimuli into spatially organized
gene regulation. Presentation presented to the UU Department of
Neurobiology & Anatomy on January 23, 2020 (hereafter referred to as
``UU Department of Neurobiology presentation'').
DP2 NS127276-01, ``Decoding neuronal activity history at
the genome through the spatially segregated inducible transcription
factors,'' submitted to NINDS, NIH, on August 20, 2020, Awarded Project
Dates: September 15, 2021-August 1, 2023.
F32 MH110141-01, ``Regulation of excitatory-inhibitory
balance by the local translation of the immediate early gene Npas4,''
submitted to NIMH, NIH, on August 10, 2015.
F32 MH110141-01A1, ``Regulation of Excitatory-Inhibitory
Balance by Local Translation of the Immediate Early Gene Npas4,''
submitted to NIMH, NIH, on December 8, 2015, Awarded Project Dates:
August 1, 2016-July 31, 2018.
F32 MH110141-01A1S1, ``Regulation of Excitatory-Inhibitory
Balance by Local Translation of the Immediate Early Gene Npas4,''
submitted to NIMH, NIH, on December 8, 2016, Awarded Project Dates:
December 1, 2016-July 31, 2017.
The falsified and/or fabricated data also were included in twenty-
three (23) figures in the following five (5) PHS grant applications:
R01 NS131809-01, ``Regulation and function of dendritic
mRNA that encodes the neuronal transcription factor Npas4,'' submitted
to NINDS, NIH, on June 6, 2022.
R01 NS133405-01, ``Assessing the impact of the inducible
transcription factor NPAS4 on spatial tuning in the mouse
hippocampus,'' submitted to NINDS, NIH, on October 5, 2022.
R01 NS111162-01A1, ``Molecular and cellular mechanisms
underlying activity dependent gene regulation in neurons,'' submitted
to NINDS, NIH, on March 5, 2019, Awarded Project Dates: December 15,
2019-November 30, 2024.
R21 MH121860-01, ``Identification of dendritically-
localized transcription factor mRNAs as a mechanism for conveying
multiple streams of information to the nucleus,'' submitted to NIMH,
NIH, on February 19, 2019.
R21 MH121860-01A1, ``Identification of dendritically-
localized transcription factor mRNAs,'' submitted to NIMH, NIH, on
March 16, 2020.
Specifically, ORI found that:
1. Respondent knowingly or intentionally combined two to three real
data sets and two to five fabricated data sets to falsely increase the
n-values reported in:
Figures 1B, 1D, 1E, 1G, 1I, 1J, 1M-1O, 1Q-1T, S2B-S2D,
S2F-S2H, S3I, S3L, S3M, and S6H of Cell 2019 and Slides 6-10, 13, and
28 of the UU Department of Neurobiology presentation representing the
quantification of NPAS4 immunohistofluorescence.
Figures 2H, 2I, 2K, 2P, 3C, 3E, 4D-4G, 4K-4N, 4P-4Q, S3G,
S5B, and S5C of Cell 2019 representing the quantification of Npas4 mRNA
or puro-PLA puncta.
Figures S1E, S1G, and S1H of Cell 2019 representing the
quantification of whole-cell clamp recordings of CA1 PN.
Figures 2 (lower panel) and 3c of F32 MH110141-01, Figures
1g, 2b, 2d, and 4 of F32 MH110141-01A1S1, and Figures 1g, 2b, 2d, and 4
of F32 MH110141-01A1 representing time points of NPAS4 quantification
after no stimulation or post-stimulation in the alveus or radiatum SR,
SO, SP, SLM, with or without the addition of an inhibitor.
2. Respondent knowingly or intentionally manipulated confocal
images that were obtained through different experimental conditions in:
Figures 1A, 1C, and 1F of Cell 2019 and Slides 6-9 of the
UU Department of Neurobiology presentation representing confocal images
of hippocampal slices immunostained for NPAS4 and Neu.
Figures S2A and S2E of Cell 2019 by manipulating and
misrepresenting the GFP signals as NPAS4 signals in wildtype mice.
Figures 1H, 1L, 1P, S3K, S6F, and S6G of Cell 2019 and
Slides 9 and 28 of the UU Department of Neurobiology presentation by
manipulating the raw images of hippocampal slices immunostained with
NPAS4 and Neu and/or ARNT1 or ARNT2 by generating a mask of NPAS4
immunofluorescent signal through GFP signal from tissue obtained from
Thy1-GFP mice to intentionally enhance the appearance of the dendritic
NPAS4 signal.
Figures S6F and S6G of Cell 2019 by manipulating the raw
images of hippocampus slices by overlaying a GFP channel over ARNT1
channel and using the multiply feature in Photoshop to restrict ARNT1
signal through GFP to enhance the ARNT1 signal in three panels.
Slides 7, 9, and 28 of the UU Department of Neurobiology
presentation by manipulating six images representing post-stimulation
with different time points by using a GFP mask overlaid on top of raw
NPAS4 immunofluorescence.
Figure 4 of DP2 NS127276-01 and panel 1 of the UU
Department of Neurobiology poster representing twelve images in columns
2-4 labeled EGR, FOS, ATF4 by mislabeling the microscope images as
immunofluorescent stained with antibodies against EGR, FOS, and ATF4
when they actually were stained with anti-NPAS4 and selected images to
support the immunofluorescence data in the ITF induction graphs.
Figure 5 of DP2 NS127276-01 representing two confocal
images in the far-right column by intentionally and selectively
enhancing the brightness of the anti-NPAS4 immunofluorescent channel
within the dashed box and left brightness unchanged in surrounding
areas of the images.
Figure 6 of DP2 NS127276-01 in twelve images in columns 2-
5 labeled Egr2, Fos, and Atf4 by intentionally mislabeling the
microscope images as RNA in situ hybridization with probes against
Egr2, Fos, and Atf4 when they actually were stained with NPAS4 probes
and intentionally selecting and quantifying images in the
quantification graphs to support the conclusions of the grant
application.
3. Respondent knowingly or intentionally manipulated the
fluorescence micrographs and their quantification graphs to augment the
role of ITFs in murine hippocampal neurons in Figures 2B-2G, 2J, 2L-2O,
3B, 3D, 3F-3H, 4C, 4J, 4O, S1A-S1D, S1F, S1I-S1J, S3A-S3F, S3H, S3J,
S3N-S3T, S5D-S5G, and S6A-S6E of Cell 2019; the falsified/fabricated
data also were included in Figures 2B-2H, 3, 4B-4E, and 5C-5G of R21
MH121860-01, Figures 2, 3B-3E, 4B-4C, 4E-4I, and 5B-5E of R21 MH121860-
01A1, Figures 3, 5, 6B, 7, 8, 10B-10D, 11A-11C, and 11E-11F in R01
NS131809-01, Figure 8 of R01 NS133405-01, and Figures 3B-3C, 3E-3I, 4B-
4I, 5, 9, 10B-10E, and 11-12 of R01 NS111162-01A1.
[[Page 25275]]
Respondent entered into a Voluntary Settlement Agreement
(Agreement) and voluntarily agreed to the following:
(1) Respondent will have his research supervised for a period of
five (5) years beginning on March 24, 2024 (the ``Supervision
Period''). Prior to the submission of an application for PHS support
for a research project on which Respondent's participation is proposed
and prior to Respondent's participation in any capacity in PHS-
supported research, Respondent will submit a plan for supervision of
Respondent's duties to ORI for approval. The supervision plan must be
designed to ensure the integrity of Respondent's research. Respondent
will not participate in any PHS-supported research until such a
supervision plan is approved by ORI. Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent's supervision plan are as
follows:
i. A committee of 2-3 senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance for a period of five (5) years from the effective date of the
Agreement. The committee will review primary data from Respondent's
laboratory on a quarterly basis and submit a report to ORI at six (6)
month intervals setting forth the committee meeting dates and
Respondent's compliance with appropriate research standards and
confirming the integrity of Respondent's research.
ii. The committee will conduct an advance review of each
application for PHS funds, or report, manuscript, or abstract involving
PHS-supported research in which Respondent is involved. The review will
include a discussion with Respondent of the primary data represented in
those documents and will include a certification to ORI that the data
presented in the proposed application, report, manuscript, or abstract
are supported by the research record.
(3) During the Supervision Period, Respondent will ensure that any
institution employing him submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported and not plagiarized
in the application, report, manuscript, or abstract.
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that his participation was not proposed on a research project
for which an application for PHS support was submitted and that he has
not participated in any capacity in PHS-supported research.
(5) During the Supervision Period, Respondent will exclude himself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
(6) Respondent will request that the following paper be corrected
or retracted:
Cell. 2019 Oct 3;179(2):373-391.e27. doi: 10.1016/
j.cell.2019.09.004.
Respondent will copy ORI and the Research Integrity Officer at UCSD
on the correspondence with the journal.
Dated: April 4, 2024.
Sheila Garrity,
Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2024-07575 Filed 4-9-24; 8:45 am]
BILLING CODE 4150-31-P
